A Phase 2 interventional study of PF-07248144 and Fulvestrant in Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer and Locally Advanced or Metastatic Non-small Cell Lung Cancer, sponsored by Pfizer. Recruiting at 43 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 23rd largest by planned enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 45 in phase 2, reaches primary completion later than 21 of the 25 other live ones, and was the 107th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
Study has two parts, Part 1 (dose escalation) and Part 2 (dose expansion). Part 1 is divided into Parts 1A, 1B, 1C, 1D and 1E and Part 2 is divided into Parts 2A, 2B, 2D and 2E. In Part 1A, single escalating doses of PF-07248144 alone will be administered to determine the maximum tolerable dose (MTD) and select the recommended dose for expansion (RDE). In Part 1B, 1C, 1D and 1E PF-07248144 will be administered in combination with either fulvestrant (Part 1B); palbociclib + letrozole (Part 1C) or PF-07220060+fulvestrant (Part 1D) or vepdegestrant (Part 1E). After the determination of the monotherapy RDE in Part 1A, PF-07248144 will be evaluated in a dose expansion cohort as a monotherapy in Part 2A.
After determination of the combination RDE from Part 1B, PF-07248144 in combination with fulvestrant, PF-07248144 will be evaluated in a combination dose expansion with fulvestrant in Part 2B. In Part 1C, PF-07248144 in combination with letrozole + palbociclib will be evaluated for dose finding to determine the MTD and RDE for this combination. After determination of the triple combination RDE from Part 1D, PF-07248144 in combination with PF-07220060 + fulvestrant will be evaluated in a combination dose-expansion cohort, Part 2D. After determination of the combination RDE from Part 1E, PF-07248144 in combination with vepdegestrant will be evaluated in a combination dose-expansion cohort, Part 2E.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-07248144 Monotherapy Escalation
Drug: PF-07248144
PF-07248144 with Fulvestrant Combination Dose Escalation
Drug: PF-07248144 · Drug: Fulvestrant
PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation
Drug: PF-07248144 · Drug: Letrozole · Drug: Palbociclib
PF-07248144 Monotherapy Dose Expansion
Drug: PF-07248144
PF-07248144 with Fulvestrant Dose Expansion
Drug: PF-07248144 · Drug: Fulvestrant
PF-07248144 with PF-07220060 +Fulvestrant
Drug: PF-07248144 · Drug: Fulvestrant · Drug: PF-07220060
PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion
Drug: PF-07248144 · Drug: Fulvestrant · Drug: PF-07220060
PF-07248144 Monotherapy Dose Expansion
Drug: PF-07248144
PF-07248144 with Vepdegestrant Combination Dose Escalation
Drug: PF-07248144 · Drug: PF-07850327, ARV-471, vepdegestrant
PF-07248144 with Vepdegestrant Combination Dose Expansion
Drug: PF-07248144 · Drug: PF-07850327, ARV-471, vepdegestrant
KAT6 Inhibitor
Endocrine Therapy
Also known as: Faslodex
Endocrine Therapy
Also known as: Femara
CDK4/6 Inhibitor
Also known as: Ibrance
CDK4 inhibitor
PROTAC (PROteolysis Targeting Chimera) ER degrader
Number of participants with dose-limiting toxicities in the Dose Escalation Arms.
Dose-limiting toxicities (DLTs)
Time frame: Up to 29 days
Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
Time frame: Up to 24 months
Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
Time frame: Up to 24 months
Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
Time frame: Up to 24 months
Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
Time frame: Up to 24 months
Single Dose: Maximum Observed Concentration (Cmax) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Single Dose: Time to Maximum concentration (Tmax) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Single Dose: AUC from time zero to time of last measurable concentration (AUClast) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Single and Multiple Dose: Terminal Elimination half-life (t1/2) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Multiple Dose: Steady-State Cmax (Cmax,ss) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Multiple Dose: Steady-state Tmax (Tmax,ss) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Multiple Dose: Steady state AUC during a dosage interval (τ) (AUCτ,ss) in the Dose Escalation and Dose Finding Arms
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Multiple Dose: Steady-state Cmin (Cmin,ss) in the Dose Escalation and Dose Finding Arms.
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Multiple Dose: Steady-state apparent total clearance (CLss/F) in the Dose Escalation and Dose Finding Arms.
Pharmacokinetic (PK) assessments for PF-07248144, PF-07220060 (Part 1D) and vepdegestrant and ARV-473 (Part 1E)
Time frame: Up to 24 months
Palbociclib trough concentrations at steady instate (Cmin,ss) in the 1C combination dose finding arm.
Pharmacokinetic (PK) assessment for palbociclib exposure.
Time frame: Up to 24 months
Peak concentrations of PF-07248144, PF-07220060 (Part 2D) and vepdegestrant and ARV-473 (Part 2E) for selected cycles in the Dose Expansion Arms
Pharmacokinetic (PK) assessment for PF-07248144, PF-07220060 (Part 2D) and vepdegestrant and ARV-473 (Part 2E)
Time frame: Up to 24 months
Trough concentrations of PF-07248144 for selected cycles in the Dose Expansion Arms
Pharmacokinetic (PK) assessment for PF-07248144 , PF-07220060 (Part 2D) and vepdegestrant and ARV-473 (Part 2E)
Time frame: Up to 24 months
Maximum Observed Concentration (Cmax) in the participants in the food effect subset in monotherapy dose expansion arm
The effect of food on the PK of PF-07248144.
Time frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
Time to Maximum concentration (Tmax) in the participants in the food effect subset in monotherapy dose expansion arm
The effect of food on the PK of PF-07248144.
Time frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
AUC from time zero to time of last measurable concentration (AUClast) in the participants in the food effect subset in monotherapy dose expansion arm
The effect of food on the PK of PF 07248144.
Time frame: Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
Amount of PF-07248144 excreted in urine relative to dose administered (%) in a sub-set of participants in monotherapy dose expansion arm.
Evaluate urine pharmacokinetic (PK) of PF-07248144.
Time frame: Up to 24 months
Renal clearance (CLr) in a sub-set of participants in monotherapy dose expansion arm
Evaluate urine pharmacokinetic (PK) of PF-07248144.
Time frame: Up to 24 months
Progression Free Survival (PFS) observed in participants in the Dose Expansion Arms
Time frame: Up to 24 months
Time to Progression (TTP) observed in participants enrolled in the Dose Expansion Arms
Time frame: Up to 24 months
Overall survival (OS) observed in participants enrolled in Dose Expansion Arms
Time frame: Up to 24 months
Best Overall Response (BOR) observed in participants in the dose expansion arms
Time frame: Up to 24 months
Duration of Response (DOR) observed in participants in the dose expansion arms
Time frame: up to 24 months
Clinical Benefit Rate (CBR) observed in participants in the Dose Expansion Arms
Time frame: up to 24 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Nov 2020 (actual). Primary completion is estimated for Aug 2029, 105 months after the start.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 105 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2029 → Aug 2029, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prifetrastat
Carcinoma, Non-Small-Cell Lung →